H. Pylori Testing Feasible for People in Community Settings
By Lori Solomon HealthDay Reporter
THURSDAY, April 18, 2024 -- Community Helicobacter pylori (HP) testing in high-risk individuals is technically feasible, according to a study published online April 3 in Clinical Gastroenterology and Hepatology.
Shria Kumar, M.D., from the University of Miami, and colleagues evaluated the results of community-based HP testing in an at-risk, underserved population. The analysis included 155 participants undergoing testing using a portable urea breath test machine.
The researchers found that 34 percent of participants had HP infection, 63 percent were negative, and 3 percent were indeterminate. HP infection was significantly more common among participants who were Hispanic/Latino (79 versus 54 percent), younger (48 versus 52 years), and non-English speakers (Spanish-speaking: 67 versus 30 percent). Among the 52 participants with infection, 42 percent were retested with confirmed eradication, 37 percent were unable to be recontacted, and 19 percent did not complete treatment. Barriers identified by participants included medication tolerability, frequent dosing, and logistics of attending a second testing session. High motivation for testing and treatment was seen among those with familiarity of the association between HP and gastric cancer.
"While our medication-focused eradication rate is 96 percent, suggesting acceptable rates of eradication based on antibiotic efficacy, an intention-to-treat analysis yields markedly lower results: among 52 with infection, only 42 percent had confirmed eradication," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.